Illumina, the dominant maker of gene-sequencing machines, is getting a more bullish outlook from RBC Capital Markets, which argues that the company's clinical business is poised for durable growth as cancer-testing demand rises and insurers pay more reliably. In a note released Sunday, RBC raised its price target on the stock to $310 from $230, a significant jump that reflects a shift in how the bank sees the company's revenue engine.
The core of the argument: Illumina's growth no longer depends on cutting prices to win lab contracts. Instead, oncology-driven test volumes and better reimbursement are expected to let the company grow revenue more cleanly. RBC projects mid-teens percentage growth in clinical sequencing over the coming years, a pace that would mark a meaningful improvement from recent quarters where pricing pressure weighed on results.
How Illumina makes money
Illumina sells two things: the sequencing instruments themselves and the consumables—reagents, flow cells, and other supplies—that labs must buy to run tests. The business model is similar to razors-and-blades: a lab installs a machine, and every subsequent test generates recurring revenue from consumables. That means growth depends on both how many new machines get placed and how heavily existing ones are used.
In recent years, Illumina has faced intense competition, particularly from rivals offering cheaper sequencing platforms. That forced the company to discount aggressively, which squeezed revenue even when test volumes were rising. RBC's new view is that this pricing pressure is easing. As insurers improve reimbursement for clinical sequencing—especially in oncology—labs can run more tests without having to pass on lower prices to patients or providers. When that happens, volume growth translates more directly into dollar growth.
The bank also highlighted Illumina's BioInsight unit, which focuses on generating large-scale biological datasets. RBC believes this business could contribute an additional 1 to 2 percentage points of growth by fiscal 2027, as drugmakers increasingly look for such data to train artificial intelligence models. The so-called Billion Cell Atlas project, which aims to map a billion human cells, is part of this effort.
What it means for investors
For investors, the key debate is about the quality of Illumina's revenue, not just the number of tests run. If oncology demand leads hospitals and labs to install more Illumina machines, each new instrument typically locks in years of consumables purchases. That recurring revenue is often valued more highly by the market than one-off equipment sales, because it is more predictable.
RBC's focus on easing pricing pressure is central to its bullish case. Better reimbursement and less discounting could allow volume growth to show up as actual revenue growth, rather than being competed away through lower average selling prices. If that happens, investors may be willing to assign a higher earnings multiple to the stock. If pricing stays tight, clinical growth could look less durable, and the $310 target would be harder to justify.
The bank also expects academic research demand to bottom out in fiscal 2027. That segment has been a drag on Illumina's overall results, as university and government labs have slowed spending. If that drag fades, clinical work becomes a larger share of the mix, which could boost overall growth rates.
Broader context
Illumina's story is part of a larger trend in healthcare: the shift toward precision medicine, where treatments are tailored to a patient's genetic profile. Oncology is at the forefront, with tests that identify specific mutations guiding therapy choices. As these tests become more standard and insurers cover them more broadly, the market for sequencing is expected to expand.
But the competitive landscape remains intense. Newer entrants have brought down the cost of sequencing dramatically, and Illumina has had to defend its market share. The company also recently completed the spinoff of its cancer blood-test unit, Grail, which had been a costly distraction. With that behind it, management has been able to focus on the core sequencing business.
RBC's price target increase is a notable vote of confidence, but it is just one analyst's view. Investors should weigh it against other perspectives and the company's own guidance. The stock's reaction to the note will depend on whether the market shares RBC's optimism about pricing and reimbursement trends.
For everyday investors, the takeaway is that Illumina's growth is increasingly tied to clinical adoption, not just research spending. If oncology testing continues to expand and reimbursement improves, the company could deliver steadier, more profitable growth. But the competitive and pricing risks remain real, and the $310 target assumes those headwinds keep fading.
